154 related articles for article (PubMed ID: 22112970)
1. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
[TBL] [Abstract][Full Text] [Related]
2. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
[TBL] [Abstract][Full Text] [Related]
3. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
[TBL] [Abstract][Full Text] [Related]
4. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
6. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
Liu FY; Yen TC; Wang JY; Yang TS
Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
[TBL] [Abstract][Full Text] [Related]
7. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
Byström P; Berglund A; Garske U; Jacobsson H; Sundin A; Nygren P; Frödin JE; Glimelius B
Ann Oncol; 2009 Jun; 20(6):1057-61. PubMed ID: 19164458
[TBL] [Abstract][Full Text] [Related]
8. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
[TBL] [Abstract][Full Text] [Related]
10. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
11. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
12. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Woff E; Hendlisz A; Garcia C; Deleporte A; Delaunoit T; Maréchal R; Holbrechts S; Van den Eynde M; Demolin G; Vierasu I; Lhommel R; Gauthier N; Guiot T; Ameye L; Flamen P
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1792-801. PubMed ID: 27072811
[TBL] [Abstract][Full Text] [Related]
13. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Lau LF; Williams DS; Lee ST; Scott AM; Christophi C; Muralidharan V
Ann Surg Oncol; 2014 Jul; 21(7):2420-8. PubMed ID: 24595797
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
Hendlisz A; Deleporte A; Delaunoit T; Maréchal R; Peeters M; Holbrechts S; Van den Eynde M; Houbiers G; Filleul B; Van Laethem JL; Ceyssens S; Barbuto AM; Lhommel R; Demolin G; Garcia C; El Mansy H; Ameye L; Moreau M; Guiot T; Paesmans M; Piccart M; Flamen P
PLoS One; 2015; 10(9):e0138341. PubMed ID: 26421426
[TBL] [Abstract][Full Text] [Related]
15. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
[TBL] [Abstract][Full Text] [Related]
16. PET scans as a predictive marker of survival in advanced colorectal cancer.
Choi M; Kollepara SL; Heilbrun LK; Smith D; Shields AF; Philip PA
Clin Colorectal Cancer; 2015 Mar; 14(1):35-40. PubMed ID: 25481195
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of advanced colorectal adenoma.
Gollub MJ; Grewal RK; Panu N; Thipphavong S; Sohn M; Zheng J; Moskowitz CS
Clin Radiol; 2014 Jun; 69(6):611-8. PubMed ID: 24581969
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
19. Early
Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
[TBL] [Abstract][Full Text] [Related]
20. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Goshen E; Davidson T; Zwas ST; Aderka D
Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
